Barbier-Torres, Lucía
Iruzubieta, Paula
Fernández-Ramos, David
Delgado, Teresa C.
Taibo, Daniel
Guitiérrez-de-Juan, Virginia
Varela-Rey, Marta
Azkargorta, Mikel
Navasa, Nicolas
Fernández-Tussy, Pablo
Zubiete-Franco, Imanol
Simon, Jorge
Lopitz-Otsoa, Fernando
Lachiondo-Ortega, Sofia
Crespo, Javier
Masson, Steven
McCain, Misti Vanette
Villa, Erica http://orcid.org/0000-0001-6388-7022
Reeves, Helen
Elortza, Felix
Lucena, Maria Isabel http://orcid.org/0000-0001-9586-4896
Hernández-Alvarez, Maria Isabel http://orcid.org/0000-0001-9586-4896
Zorzano, Antonio
Andrade, Raúl J.
Lu, Shelly C.
Mato, José M.
Anguita, Juan http://orcid.org/0000-0003-2061-7182
Rincón, Mercedes
Martínez-Chantar, María Luz
Article History
Received: 24 February 2017
Accepted: 30 October 2017
First Online: 12 December 2017
Competing interests
: M.R. and M.L.M.-C. have received funding/grant support for research projects from Mitotherapeutix; they have served as a consultant/advisor for Mitotherapeutix. J.M.M. consults for, advises for, and owns stock in Owl. He consults for and advises for Abbott. He consults for Galmed. The remaining authors declare no competing financial interests.